Elevar Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Lirafugratinib as a Treatment for Patients with Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements

NDA FilinglirafugratinibPositive

AI Analysis

Summary

Elevar Therapeutics submitted a marketing authorization application to the European Medicines Agency for lirafugratinib as a second-line treatment for advanced/metastatic cholangiocarcinoma patients with FGFR2 fusions or rearrangements.

Outcome Details

Marketing authorization application submitted to EMA for second-line treatment

Importance:7/10

Sentiment:

0.70

EMA submissiononcologycholangiocarcinomaFGFR2regulatory milestone

Related Companies

$INBP

Read the original article

Published by GlobeNewswire Pharma on September 15, 2026 3:49 PM

Read Original